ACOs Can’t Tap Into 340B Drug Discounts Provided To Member Safety Net Facilities, HRSA Clarifies
The clarification could answer biopharma industry concerns about how 340B rules fit in the new Medicare accountable care organization program; HRSA also advises that drug shortage allocation plans may not discriminate against 340 providers.
You may also be interested in...
Proposed rule would implement how civil monetary penalties will be applied to manufacturers that “knowingly and intentionally” deny 340B prices to eligible health care providers.
The ranking member on the Senate Judiciary Committee sends a letter to the University of Alabama Hospital seeking details on how it has changed the admission status and treatment of patients to get 340B drug discounts for patients who would not have been eligible otherwise.
The Health Resources and Services Administration has begun random and targeted audits of health care providers participating in the federal 340B drug discount program to help ensure products are not being diverted for other uses or resulting in manufacturers paying double discounts to Medicaid.